Topotarget gains on belinostat data

Topotarget A/S (CSE:TOPO) gained DKK0.61 (33%) to DKK2.46 on Tuesday after reporting that once-daily IV belinostat led to an objective response rate (ORR) that is "on par" with that of competing drugs Folotyn pralatrexate and Istodax romidepsin in the Phase II BELIEF (PXD101-CLN-19) trial to treat relapsed or refractory peripheral T cell lymphoma (PTCL). Last September, Topotarget said top-line data showed belinostat met the primary endpoint in the trial of an ORR of 20% or greater. The open-label, international trial enrolled 129 patients who failed one or more systemic therapy (see BioCentury Extra, Sept. 21, 2012).

Topotarget said partner Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) plans to submit an NDA to FDA for belinostat in mid-2013. Spectrum, which has rights from Topotarget to co-develop and commercialize the small molecule histone deacetylase (HDAC) inhibitor in North America and India, was up $0.05 to $11.54 on Tuesday. ...